Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study

Roderick C N Van Den Bergh, Hanna Vasarainen, Henk G. Van Der Poel, Jenneke J. Vis-Maters, John B. Rietbergen, Tom Pickles, Erik B. Cornel, Riccardo Valdagni, Joris J. Jaspars, John Van Der Hoeven, Frederic Staerman, Eric H G M Oomens, Antti Rannikko, Stijn Roemeling, Ewout W. Steyerberg, Monique J. Roobol, Fritz H. Schröder, Chris H. Bangma

Research output: Contribution to journalArticlepeer-review


Study Type - Therapy (prospective cohort) Level of Evidence 2b Objective To evaluate the short-term outcomes of the prospective international Prostate Cancer Research International: Active Surveillance ('PRIAS') study (Dutch Trial Register NTR1718), as active surveillance (AS) for early prostate cancer might provide a partial solution to the current overtreatment dilemma in this disease. Patients and methods The first 500 (of >950) participants with asymptomatic T1c/T2 prostate cancer, with a prostate-specific antigen (PSA) level of ≤10.0 ng/mL, a PSA density of 6 or more than two positive biopsy cores. There was a relatively unfavourable PSA doubling time of 0-10 years in 53% (102/194) and 62% (33/53) of men with favourable and unfavourable re-biopsy results, respectively. After RP, four of 24 (17%) men had T3 disease and 12 (50%) had a Gleason score of >6. Conclusion AS seems feasible, but mortality outcomes are unknown. A strict follow-up protocol including standard 1-year repeat biopsies resulted in a quarter of men stopping AS after 2 years.

Original languageEnglish
Pages (from-to)956-962
Number of pages7
JournalBJU International
Issue number7
Publication statusPublished - Apr 2010


  • Active surveillance
  • Biopsy
  • Outcomes
  • Prostate cancer
  • PSA
  • Watchful waiting

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study'. Together they form a unique fingerprint.

Cite this